Highlights include the need for gene panel testing, dealing with small specimens, and recommended use of liquid biopsy where tissue is inadequate or unavailable. (The latter matches NCCN guidelines, too.)
See coverage at Genomeweb here, and in other trade press here, here. As shown in the figure below, lung cancer genomics have become vastly more complicated over several years. (For one sample, see an article on targeting MET, here.)
|click to enlarge|
See another article on new international collaborations re lung cancer staging, here.